Understanding how Hodgkin lymphoma cells evade the immune system
Analysis and Therapeutic Targeting of the Linear-Ubiquitination Pathway in Hodgkin Lymphoma
This study is looking at how Hodgkin lymphoma cells manage to hide from the immune system and keep growing, focusing on a specific protein complex, and it aims to find new ways to improve treatments for patients dealing with advanced or returning cases of this cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11097159 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which Hodgkin lymphoma (HL) cells survive and evade the immune system, particularly focusing on a protein complex called LUBAC. Using advanced techniques like CRISPR screening, the study aims to uncover how these cancer cells escape immune detection and continue to thrive despite treatment. By identifying the molecular pathways involved, the research seeks to develop new therapeutic strategies that could improve outcomes for patients with advanced or relapsed HL. The ultimate goal is to enhance the effectiveness of existing treatments and potentially lead to the discovery of novel therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Hodgkin lymphoma, particularly those with advanced or relapsed disease.
Not a fit: Patients with early-stage Hodgkin lymphoma or those who have not experienced relapse may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and higher survival rates for patients with Hodgkin lymphoma.
How similar studies have performed: Other research has shown promise in targeting immune evasion mechanisms in various cancers, suggesting that this approach could be effective for Hodgkin lymphoma as well.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Yang, Yibin — Research Inst of Fox Chase Can Ctr
- Study coordinator: Yang, Yibin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.